CliffBio
biologic

Beovu

brolucizumab-dbll

Loss of exclusivityMay 2034projected — 12-year biologic exclusivity estimate
CompanyNovartis Pharmaceuticals Corporation

Drug detail

Brand nameBeovu
Active ingredientbrolucizumab-dbll
Strength6MG/0.05ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalMay 2022
Marketing statusRx

More from Novartis Pharmaceuticals Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Beovu patent cliff — loss of exclusivity May 2034 | CliffBio